93 patents
Page 3 of 5
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
10 Feb 22
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 20 Oct 21
Utility
Targeting Ligands
3 Feb 22
Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target.
Zhen Li, Tao Pei, Agnieszka Glebocka, Michael Lawler, Fred Fleitz, Erich Altenhofer, Pankaj Kumar
Filed: 17 Jun 21
Utility
Alpha-v BETA-6 Integrin Ligands and Uses Thereof
27 Jan 22
Integrin ligands having serum stability and affinity for αvβ6 integrins are described.
Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
Filed: 14 Oct 21
Utility
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
4 Jan 22
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 31 Jan 20
Utility
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
4 Jan 22
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene.
Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
Filed: 31 Jan 20
Utility
RNAi inhibition of alpha-ENaC expression
28 Dec 21
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Filed: 24 Jan 20
Utility
Rnai Agents for Hepatitis B Virus Infection
23 Dec 21
Described are methods for inhibition of Hepatitis B virus gene expression or treating symptoms and/or diseases associated with Hepatitis B virus infection.
Bruce D. GIVEN, James C. HAMILTON, Thomas SCHLUEP, Maria Gloria BEUMONT, Oliver LENZ, Ronald Cornelis Marie KALMEIJER
Filed: 6 Aug 21
Utility
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
21 Dec 21
RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described.
Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
Filed: 12 Sep 19
Utility
Alpha-v beta-6 integrin ligands and uses thereof
23 Nov 21
Integrin ligands having serum stability and affinity for αvβ6 integrins are described.
Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
Filed: 30 Apr 19
Utility
Targeting ligands
16 Nov 21
Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target.
Zhen Li, Tao Pei, Agnieszka Glebocka, Michael Lawler, Fred Fleitz, Erich Altenhofer, Pankaj Kumar
Filed: 10 Apr 19
Utility
RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use
30 Sep 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression.
Anthony Nicholas, Tao Pei, Zhao Xu, Casi Schienebeck, Zhi-Ming Ding
Filed: 26 Mar 21
Utility
Organic compositions to treat HSF1-related diseases
17 Aug 21
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
Filed: 14 May 19
Utility
RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
5 Aug 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
Zhen Li, Rui Zhu, So Wong
Filed: 15 Apr 21
Utility
5′-cyclo-phosphonate modified nucleotides
3 Aug 21
Zhen Li, Tao Pei, Michael Lawler
Filed: 3 Dec 18
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
29 Jul 21
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 7 Apr 21
Utility
Organic compositions to treat APOC3-related diseases
20 Jul 21
The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.
Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
Filed: 6 Feb 19
Utility
Targeting Ligands For Therapeutic Compounds
24 Jun 21
Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo.
David B Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
Filed: 24 Feb 21
Utility
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
17 Jun 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
Filed: 19 Feb 21
Utility
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
4 May 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
Zhen Li, Rui Zhu, So Wong
Filed: 13 Sep 18
Utility
Rnai Agents for Hepatitis B Virus Infection
8 Apr 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
Filed: 11 Aug 20